Brief: Aldeyra Therapeutics Announces Improvement From Baseline In Retinal Function In Phase 2 Clinical Trial Of ADX‑2191
29/06/2023 12:06
June 29 (Reuters) - Aldeyra Therapeutics Inc ALDX.O :
* ALDEYRA THERAPEUTICS ANNOUNCES IMPROVEMENT FROM BASELINE
IN
RETINAL FUNCTION IN PHASE 2 CLINICAL TRIAL OF ADX-2191 IN
PATIENTS WITH RETINITIS PIGMENTOSA
* ALDEYRA THERAPEUTICS INC - ADX-2191 WAS WELL TOLERATED AND
NO
SAFETY CONCERNS WERE IDENTIFIED
* ALDEYRA THERAPEUTICS INC - NO TREATMENT-RELATED ADVERSE
EVENTS
ASSOCIATED WITH RETINAL MORPHOLOGY WERE OBSERVED
* ALDEYRA THERAPEUTICS INC - NO SERIOUS ADVERSE EVENTS WERE
REPORTED, AND NO PATIENTS DISCONTINUED DUE TO ADVERSE EVENTS
Source text for Eikon: ID:nBw5fSmP6a
Further company coverage: ALDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora